5-MeO-DPT

5-MeO-DPT
Legal status
Legal status	DE: NpSG (Industrial and scientific use only) ; UK: Class A ;
Identifiers
	IUPAC name N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine;
CAS Number	69496-75-9 ;
PubChem CID	14011047;
ChemSpider	14106484 ;
UNII	AYW60P516B;
ChEMBL	ChEMBL169328 ;
CompTox Dashboard (EPA)	DTXSID70219723 ;
Chemical and physical data
Formula	C17H26N2O
Molar mass	274.408 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	193 to 194 °C (379 to 381 °F)
	SMILES CCCN(CCC)CCc2c[nH]c1ccc(cc12)OC;
	InChI InChI=1S/C17H26N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h6-7,12-13,18H,4-5,8-11H2,1-3H3 ; Key:PNHPVNBKLQWBKH-UHFFFAOYSA-N ;
	(what is this?) (verify)

5-MeO-DPT (also known as 5-methoxy-N,N-Dipropyltryptamine), is a psychedelic and entheogenic designer drug.[1][2][3][4]

Chemistry

The full chemical name is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine. It is classified as a tryptamine derivative.

Effects

Little is known about the subjective effects of 5-MeO-DPT, but the nature of the compound is probably comparable to 5-MeO-DiPT, 5-MeO-DMT, or DPT, which are also psychedelic tryptamines/indoles. However, the duration of the above-mentioned drugs vary considerably.

Dosage

5-MeO-DPT is orally active, with 3-10 mg representing a fully effective dosage for most users. Effects begin within three hours, and usually last 4 hours.

References

Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology. 68 (2): 155–8. doi:10.1007/BF00432133. PMID 6776558. S2CID 1674481.
Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (June 2007). "Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry". Forensic Toxicology. 25 (1): 1–7. doi:10.1007/s11419-006-0018-y. S2CID 9906203.
Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). "Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry". Forensic Toxicology. 32 (1): 154–61. doi:10.1007/s11419-013-0208-3. S2CID 25134125.
Pham DN, Chadeayne AR, Golen JA, Manke DR (May 2021). "5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate". Acta Crystallographica Section E. 77 (Pt 5): 522–526. doi:10.1107/S2056989021003753. PMC 8100262. PMID 34026257.

External links

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid6776558-1] Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities". Psychopharmacology. 68 (2): 155–8. doi:10.1007/BF00432133. PMID 6776558. S2CID 1674481.

[2] Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (June 2007). "Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry". Forensic Toxicology. 25 (1): 1–7. doi:10.1007/s11419-006-0018-y. S2CID 9906203.

[3] Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). "Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry". Forensic Toxicology. 32 (1): 154–61. doi:10.1007/s11419-013-0208-3. S2CID 25134125.

[pmid34026257-4] Pham DN, Chadeayne AR, Golen JA, Manke DR (May 2021). "5-Meth-oxy-N,N-di-n-propyl-tryptamine (5-MeO-DPT): freebase and fumarate". Acta Crystallographica Section E. 77 (Pt 5): 522–526. doi:10.1107/S2056989021003753. PMC 8100262. PMID 34026257.